CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report

CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report

Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical pharmacy and therapeutics 2006-12, Vol.31 (6), p.645-648
Hauptverfasser: Cay, H F, Gungor, HA, Sezer, I, Kacar, C, Balci, N
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 648
container_issue 6
container_start_page 645
container_title Journal of clinical pharmacy and therapeutics
container_volume 31
creator Cay, H F
Gungor, HA
Sezer, I
Kacar, C
Balci, N
description Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.
doi_str_mv 10.1111/j.1365-2710.2006.00779.x
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_19566107</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19566107</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_195661073</originalsourceid><addsrcrecordid>eNqNjEFLAzEUhIMouFb_wzt52zXJ2g3bi5S6pSeVdu8lbt9q2jSJeam4_94VxLPDwMDMxzAGghdi1N2-EGU1zaUaC8l5VXCuVF18nbHsbzhnGZdVnd8rqS7ZFdGej6SSZcZoMd80sG5entftDOa7T4yEgH2PXQLfQ_u0zLUN7xpere8OGB_gEY8DWuN0Mt6BcaB_fBisJ-PegIJ3u8GaZAjCyKBLM9DQ6fE3YvAxXbOLXlvCm9-csNtl0y5WeYj-44SUtkdDHVqrHfoTbUU9rSrBVflv8BvmZ1W8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19566107</pqid></control><display><type>article</type><title>CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report</title><source>Wiley Online Library All Journals</source><creator>Cay, H F ; Gungor, HA ; Sezer, I ; Kacar, C ; Balci, N</creator><creatorcontrib>Cay, H F ; Gungor, HA ; Sezer, I ; Kacar, C ; Balci, N</creatorcontrib><description>Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/j.1365-2710.2006.00779.x</identifier><language>eng</language><ispartof>Journal of clinical pharmacy and therapeutics, 2006-12, Vol.31 (6), p.645-648</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cay, H F</creatorcontrib><creatorcontrib>Gungor, HA</creatorcontrib><creatorcontrib>Sezer, I</creatorcontrib><creatorcontrib>Kacar, C</creatorcontrib><creatorcontrib>Balci, N</creatorcontrib><title>CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report</title><title>Journal of clinical pharmacy and therapeutics</title><description>Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.</description><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNjEFLAzEUhIMouFb_wzt52zXJ2g3bi5S6pSeVdu8lbt9q2jSJeam4_94VxLPDwMDMxzAGghdi1N2-EGU1zaUaC8l5VXCuVF18nbHsbzhnGZdVnd8rqS7ZFdGej6SSZcZoMd80sG5entftDOa7T4yEgH2PXQLfQ_u0zLUN7xpere8OGB_gEY8DWuN0Mt6BcaB_fBisJ-PegIJ3u8GaZAjCyKBLM9DQ6fE3YvAxXbOLXlvCm9-csNtl0y5WeYj-44SUtkdDHVqrHfoTbUU9rSrBVflv8BvmZ1W8</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Cay, H F</creator><creator>Gungor, HA</creator><creator>Sezer, I</creator><creator>Kacar, C</creator><creator>Balci, N</creator><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20061201</creationdate><title>CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report</title><author>Cay, H F ; Gungor, HA ; Sezer, I ; Kacar, C ; Balci, N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_195661073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cay, H F</creatorcontrib><creatorcontrib>Gungor, HA</creatorcontrib><creatorcontrib>Sezer, I</creatorcontrib><creatorcontrib>Kacar, C</creatorcontrib><creatorcontrib>Balci, N</creatorcontrib><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cay, H F</au><au>Gungor, HA</au><au>Sezer, I</au><au>Kacar, C</au><au>Balci, N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><date>2006-12-01</date><risdate>2006</risdate><volume>31</volume><issue>6</issue><spage>645</spage><epage>648</epage><pages>645-648</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>Anti-tumour necrosis factor (TNF)-alpha agents promise better disease control for treatment of inflammatory arthritides which are resistant to classical disease-modifying treatment and provide better functional outcome. But these agents are not free of adverse events. The exact relationship between use of anti-TNF drugs and development of demyelination cannot be established yet. Here we present a case of a 36-year-old man who developed demyelination in the cervical spinal cord while he was being treated with etanercept for ankylosing spondylitis.</abstract><doi>10.1111/j.1365-2710.2006.00779.x</doi></addata></record>
fulltext fulltext
identifier ISSN: 0269-4727
ispartof Journal of clinical pharmacy and therapeutics, 2006-12, Vol.31 (6), p.645-648
issn 0269-4727
1365-2710
language eng
recordid cdi_proquest_miscellaneous_19566107
source Wiley Online Library All Journals
title CASE REPORT: Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A57%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CASE%20REPORT:%20Adverse%20effect%20of%20TNF-alpha%20blocker?%20Demyelination%20in%20an%20ankylosing%20spondylitis%20patient:%20a%20case%20report&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Cay,%20H%20F&rft.date=2006-12-01&rft.volume=31&rft.issue=6&rft.spage=645&rft.epage=648&rft.pages=645-648&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1111/j.1365-2710.2006.00779.x&rft_dat=%3Cproquest%3E19566107%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19566107&rft_id=info:pmid/&rfr_iscdi=true